Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Lymphoma / Leukemia / Myeloma News

Cole Foundation Injects $2.5 Million To Bolster Leukemia Research

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Pediatrics / Children's Health
Article Date: 25 May 2009 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Canada has received new support to recruit some of its best minds in pediatric leukemia research, thanks to the Cole Foundation. The family foundation has generously pledged $2.5 million to support up-and-coming, Montreal-based researchers at the Université de Montréal, McGill University and the Université du Québec's Institut national de la recherche scientifique - Institut Armand-Frappier. The Cole Foundation investment will include: Building on prior investments

This new support builds on the Cole Foundation's Fellowship Programme, which was created to encourage young researchers in search of a cure for pediatric leukemia and related diseases. This year, the Cole Foundation is injecting another $425,000 to propel the work of another 13 Cole Fellows. Since 2007, the Cole Foundation has generously funded some 31 post-doctoral and graduate research fellowships at the three institutions.

"The faculties of medicine at the Université de Montréal and McGill University, along with the Institut Armand-Frappier, produce scientists who are at the forefront of the international battle against pediatric leukemia," said Barry Cole, president of the Cole Foundation. "These new investments, coupled with our ongoing Cole Fellowships, will serve as important tools to empower tomorrow's scientists - right here in Montreal - so they may find new ways to conquer pediatric leukemia and related diseases."

2009 Cole Fellows

Of the 13 new recipients announced for 2009, 10 will work at Université de Montréal-affiliated institutions such as the Institute for Research in Immunology Cancer (IRIC), Sainte-Justine University Hospital Research Center and Maisonneuve-Rosemont Hospital. At McGill, three Cole Fellows will work from the affiliated McGill University Health Centre and Lady Davis Research Centre of the Jewish General Hospital.

The newly announced 2009 Cole Fellows are: Source:
Sylvain-Jacques Desjardins
University of Montreal




Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is Chemotherapy? What Are The Side Effects Of Chemotherapy?
22 Jul 2009
Chemotherapy is the use of chemicals (medication) to treat disease - more specifically, it usually refers to the destruction of cancer cells. However, chemotherapy also includes the use of antibiotics or other medications to treat any disease...


CML Therapy Side Effects image CML Therapy Side Effects

Even "targeted" therapy for chronic myeloid leukemia is not without side effects. Some, like low blood counts, are serious. Hear how one patient, along with her oncologist, Dr. Neil Shah of UCLA, managed the side effects of her CML treatment...

Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

View more videos...